Randy Mintz, MD
Interventional Cardiology · Voorhees, NJNPI 1265403984
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,765 of the $12,718 with a category attached, or 84.6%. 28 manufacturers reported payments, led by Medtronic at 26.0% of the total.
Across 273 payments — averaging $46.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Boston Scientific$2K
- Avinger Inc.$2K
- Abiomed$982
- Shockwave Medical, Inc$933
- Inari Medical, Inc.$853
- plus $3K from 22 others
Across 1 payment — averaging $1221.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$1K
What the payments were for
- Travel & lodging$1,95215%
- Food & beverage$10,76585%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 31 | $3,302 |
| Boston Scientific | 101 | $2,061 |
| Avinger Inc. | 35 | $1,946 |
| Abiomed | 13 | $982 |
| Shockwave Medical, Inc | 18 | $933 |
| Inari Medical, Inc. | 7 | $853 |
| Penumbra, Inc. | 13 | $573 |
| Endologix LLC | 5 | $515 |
| Abbott | 6 | $444 |
| Stryker | 2 | $192 |
| AstraZeneca | 10 | $173 |
| Cardiovascular Systems Inc. | 3 | $150 |
| Novo Nordisk | 1 | $118 |
| W. L. Gore & Associates, Inc. | 5 | $95 |
| Philips North America LLC | 2 | $45 |
| Siemens Medical Solutions USA, Inc. | 2 | $44 |
| Pfizer | 3 | $42 |
| Irhythm Technologies, Inc. | 3 | $41 |
| E.r. Squibb & Sons, L.L.C. | 3 | $34 |
| Recor Medical Inc | 1 | $31 |
| Novartis | 2 | $27 |
| Chiesi USA, Inc. | 1 | $22 |
| Bard Peripheral Vascular, Inc. | 1 | $20 |
| Teleflex LLC | 1 | $19 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $15 |
| Cordis US CORP. | 1 | $14 |
| Biotronik Inc. | 1 | $14 |
| Tactile Systems Technology Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Resolute$1,979
- PANTHERIS$1,140
- FLOWTRIEVER CATHETER, S$799
- CT THROMBECTOMY SYSTEM KIT$799
- Impella$455
- ENDOCROSS Device$397
- Torus Stent Graft System$397
- Indigo System$357
- AVVIGO Guidance System$318
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$185
- SYMPLICITY G3$169
- Xience Sierra Coronary Stent$133
- Diamondback Peripheral$129
- Xience Sierra Coronary Stent System$127
- FFRangio$127
- RYBELSUS$118
- ARTIX MT$104
- IN.PACT Admiral$104
- SYNERGY$100
How this compares
$12,718 in reported general payments places this provider in the 65th percentile of 166 interventional cardiology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 29 | $36,567 |
| XareltoRivaroxaban | 12 | $18,831 |
| Atorvastatin Calcium | 73 | $692 |
| Metoprolol Succinate | 44 | $384 |
| ClopidogrelClopidogrel Bisulfate | 17 | $308 |
| Ezetimibe | 15 | $298 |
| Cilostazol | 14 | $258 |
| Lisinopril | 31 | $255 |
| Metoprolol Tartrate | 26 | $196 |
| Rosuvastatin Calcium | 12 | $147 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 16 | $110 |
| Amlodipine Besylate | 17 | $67 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $42 | $36,56729 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 166 interventional cardiology providers in New Jersey.
Other interventional cardiology in Voorhees
- Rita ButlerVoorhees$15K
- Ankitkumar PatelGlen Ridge$408K
- Ziad AbbudOcean$360K
- Ramin HastingsHasbrouck Heights$295K
- Michael LimHackensack$215K
- Darshan GodkarCedar Knolls$194K
- Ryan KapleHackensack$178K
- Matthew SayboltEatontown$175K
- Daniel KissEatontown$172K
- Kintur SanghviBordentown$139K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.